CP-383 / Tasca Therapeutics - LARVOL DELTA

Tasca Therapeutics Doses First Patient in Phase 1/2 Dose Escalation and Expansion Trial Evaluating CP-383 in Advanced Solid Tumors (Businesswire) - "The Phase 1/2 trial is a multi-center, open-label study evaluating the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CP-383 in patients with advanced or metastatic solid tumors."

Trial status • Solid Tumor

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1/2 | N=150 | Recruiting | Sponsor: Tasca Therapeutics | Not yet recruiting ➔ Recruiting

Enrollment open • Bladder Cancer • Colorectal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1/2 | N=150 | Not yet recruiting | Sponsor: Tasca Therapeutics

New P1/2 trial • Bladder Cancer • Colorectal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

Tasca Therapeutics Launches with $52 Million Series A Financing to Develop Small Molecule Inhibitors for Multiple Oncology Indications (Businesswire) - "Tasca Therapeutics Corp...today announced a $52 million Series A financing, co-led by Regeneron Ventures and Cure Ventures, with participation by Invus Group. This funding will be used to advance Tasca’s novel drug discovery platform, progress its lead program, CP-383, into Phase 1/2 clinical proof-of-concept studies, and to expand its drug candidate pipeline."

Financing • Oncology